Document is current
Any future updates will be listed below
-
Authors
Lee, Chel Hee
Banoei, Mohammad M.
Ansari, Mariam
Cheng, Matthew P.
Lamontagne, Francois
Griesdale, Donald
Lasry, David E.
Demir, Koray
Dhingra, Vinay
Tran, Karen C.
Lee, Terry
Burns, Kevin
Sweet, David
Marshall, John
Slutsky, Arthur
Murthy, Srinivas
Singer, Joel
Patrick, David M.
Lee, Todd C.
Boyd, John H.
Walley, Keith R.
Fowler, Robert
Haljan, Greg
Vinh, Donald C.
Mcgeer, Alison
Maslove, David
Mann, Puneet
Donohoe, Kathryn
Hernandez, Geraldine
Rocheleau, Genevieve
Trahtemberg, Uriel
Kumar, Anand
Lou, Ma
dos Santos, Claudia
Baker, Andrew
Russell, James A.
Winston, Brent W.
,
Russell, J. A.
Walley, K. R.
Boyd, J.
Lee, T.
Singer, J.
Sweet, D.
Tran, K.
Reynolds, S.
Haljan, G.
Cheng, M.
Vinh, D.
Lee, T.
Lamontagne, F.
Winston, B.
Rewa, O.
Marshall, J.
Slutsky, A.
McGeer, A.
Sivanantham, V.
Fowler, R.
Maslove, D.
Patrigeon, S. Perez
Burns, K. D.
-
Funding
Funding for this research was provided by:
National Grant Review 2021, The Lung Association Grant
National Grant Review 2022, The Lung Association Grant
University of Calgary Catalyst Grant
- License Information
-
More Information
Article History
Received: 12 December 2023
Accepted: 19 February 2024
First Online: 27 February 2024
Declarations
:
: The authors declare no conflicts of interest, financial or otherwise, except Dr. James Russell who discloses the following: COI: DR. JAMES A. RUSSELL AB, MD, FRCPC FINANCIAL DISCLOSURE (last 36 months). Dr. Russell reports patents owned by the University of British Columbia (UBC) that are related to (1) the use of PCSK9 inhibitor(s) in sepsis, (2) the use of vasopressin in septic shock, and (3) a patent owned by Ferring for the use of selepressin in septic shock. Dr. Russell is an inventor on these patents. Dr. Russell was a founder, Director, and shareholder in Cyon Therapeutics Inc. (now closed) and is a shareholder in Molecular You Corp. Dr. Russell is a Senior Research Advisor of the British Columbia, Canada Post COVID—Interdisciplinary Clinical Care Network (PC-ICCN). Dr. Russell is no longer actively consulting for any industry. Dr. Russell reports receiving consulting fees in the last three years from: (1) SIB Therapeutics LLC (developing a sepsis drug). (2) Ferring Pharmaceuticals (manufactures vasopressin and developing selepressin). (3) Dr. Russell was a funded member of the Data and Safety Monitoring Board (DSMB) of an NIH-sponsored plasma trial in COVID-19 (PASS-IT-ON) (2020–2021). (4) PAR Pharma (sells prepared bags of vasopressin). Dr. Russell reports receiving an investigator-initiated grant from Grifols (entitled "Is HBP a mechanism of albumin's efficacy in human septic shock?") that was provided to and administered by UBC. Dr. Russell has received grants for COVID-19 research: 4 from the Canadian Institutes of Health Research (CIHR) and three from the St. Paul's Foundation (SPF). Dr. Russell was a non-funded Science Advisor and member of the Government of Canada COVID-19 Therapeutics Task Force (June 2020–2021).
